Back to search results

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Abroad (travel likely)RecruitingPHASE3

Conditions

Enthesitis-related Arthritis · Juvenile Psoriatic Arthritis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Ja0005 50646, Calgary, Canada

  • Ja0005 50644, Montreal, Canada

  • Ja0005 50645, Saskatoon, Canada

  • Ja0005 40777, Indre-et-Loire, France

  • Ja0005 40510, Le Kremlin-Bicêtre, France

  • Ja0005 40778, Paris, France

  • Ja0005 40776, Poitiers, France

  • Ja0005 40369, Berlin, Germany

  • Ja0005 40356, Dresden, Germany

  • Ja0005 40072, Freiburg im Breisgau, Germany

  • Ja0005 40852, Hamburg, Germany

  • Ja0005 40787, Sankt Augustin, Germany

  • Ja0005 40779, Sendenhorst, Germany

  • Ja0005 40427, Tübingen, Germany

  • Ja0005 40720, Krakow, Poland

  • Ja0005 40780, Sosnowiec, Poland

  • Ja0005 40781, Esplugues de Llobregat, Spain

  • Ja0005 40100, Madrid, Spain

  • Ja0005 40782, Valencia, Spain

  • Ja0005 40786, Bristol, United Kingdom

  • Ja0005 40783, Manchester, United Kingdom

  • Ja0005 40785, Nottingham, United Kingdom

  • Ja0005 40784, Stroke-on-trent, United Kingdom

Study leads

  • UCB Cares

    Study Director

    001 844 599 2273

View source on ClinicalTrials.gov(opens in a new tab)